Jagged Ends of Urinary Cell-Free DNA Assessed in Bladder Cancer Detection
By LabMedica International staff writers Posted on 24 May 2021 |

Image: Schematic of workflow for urinary DNA jagged end analysis. Urinary DNA was subjected to an end-repair process; JI-U = jagged index–unmethylated (Photo courtesy of The Chinese University of Hong Kong)
Bladder cancer is where a growth of abnormal tissue, known as a tumor, develops in the bladder lining. In some cases, the tumor spreads into the bladder muscle. The most common symptom of bladder cancer is blood in the urine, which is usually painless.
Cell-free DNA (cfDNA) molecules in plasma consist of fragments of DNA. Much interest has been focused recently on the fragmentation patterns of such DNA molecules. The fragment sizes and ends, for example, display nucleosomal features in relation to the tissues of origin. When compared with plasma DNA, urinary cfDNA molecules exhibit a different size profile; therefore, urinary DNA molecules are much more fragmented than plasma DNA.
Medical Scientists at The Chinese University of Hong Kong (Shatin, Hong Kong, China) and their colleagues obtained bisulfite sequencing data of urinary DNA from a previous study, including 46 patients with bladder cancer, all of whom were urothelial cell carcinoma, and 39 control participants with hematuria, but without detectable bladder cancer. Among patients with bladder cancer, 37 had non–muscle-invasive bladder cancer and nine patients with muscle-invasive bladder cancer.
Urinary cfDNA was extracted using the Wizard Plus Minipreps DNA Purification System (Promega, Madison, WI, USA) with the addition of guanidine thiocyanate to urine before mixing with resin. DNA libraries were sequenced using the Illumina HiSeq 2500 or NextSeq 500 with a 41 bp × 2 paired-end sequencing protocol (Illumina, San Diego, CA, USA). Incorporation of unmethylated cytosines during the repair of the jagged ends lowered the apparent methylation levels measured by bisulfite sequencing and were used to calculate a jagged end index. This approach is called jagged end analysis by sequencing.
The investigators reported that the jagged end index of urinary cfDNA was higher than that of plasma DNA. The jagged end index profile of plasma DNA displayed several strongly oscillating major peaks at intervals of approximately 165 bp (i.e., nucleosome size) and weakly oscillating minor peaks with periodicities of approximately 10 bp. In contrast, the urinary DNA jagged end index profile showed weakly oscillating major peaks, but strongly oscillating minor peaks. The jagged end index was generally higher in nucleosomal linker DNA regions. The 46 Patients with bladder cancer had lower jagged end indexed of urinary DNA than 39 participants without bladder cancer. The area under the curve for differentiating between patients with and without bladder cancer was 0.83.
The authors concluded that jagged ends represent a property of urinary cfDNA. The generation of jagged ends might be related to nucleosomal structures, with enrichment in linker DNA regions. Jagged ends of urinary DNA could potentially serve as a new biomarker for bladder cancer detection. The study was published in the April, 2021 issue of the journal Clinical Chemistry.
Related Links:
The Chinese University of Hong Kong
Promega
Illumina
Cell-free DNA (cfDNA) molecules in plasma consist of fragments of DNA. Much interest has been focused recently on the fragmentation patterns of such DNA molecules. The fragment sizes and ends, for example, display nucleosomal features in relation to the tissues of origin. When compared with plasma DNA, urinary cfDNA molecules exhibit a different size profile; therefore, urinary DNA molecules are much more fragmented than plasma DNA.
Medical Scientists at The Chinese University of Hong Kong (Shatin, Hong Kong, China) and their colleagues obtained bisulfite sequencing data of urinary DNA from a previous study, including 46 patients with bladder cancer, all of whom were urothelial cell carcinoma, and 39 control participants with hematuria, but without detectable bladder cancer. Among patients with bladder cancer, 37 had non–muscle-invasive bladder cancer and nine patients with muscle-invasive bladder cancer.
Urinary cfDNA was extracted using the Wizard Plus Minipreps DNA Purification System (Promega, Madison, WI, USA) with the addition of guanidine thiocyanate to urine before mixing with resin. DNA libraries were sequenced using the Illumina HiSeq 2500 or NextSeq 500 with a 41 bp × 2 paired-end sequencing protocol (Illumina, San Diego, CA, USA). Incorporation of unmethylated cytosines during the repair of the jagged ends lowered the apparent methylation levels measured by bisulfite sequencing and were used to calculate a jagged end index. This approach is called jagged end analysis by sequencing.
The investigators reported that the jagged end index of urinary cfDNA was higher than that of plasma DNA. The jagged end index profile of plasma DNA displayed several strongly oscillating major peaks at intervals of approximately 165 bp (i.e., nucleosome size) and weakly oscillating minor peaks with periodicities of approximately 10 bp. In contrast, the urinary DNA jagged end index profile showed weakly oscillating major peaks, but strongly oscillating minor peaks. The jagged end index was generally higher in nucleosomal linker DNA regions. The 46 Patients with bladder cancer had lower jagged end indexed of urinary DNA than 39 participants without bladder cancer. The area under the curve for differentiating between patients with and without bladder cancer was 0.83.
The authors concluded that jagged ends represent a property of urinary cfDNA. The generation of jagged ends might be related to nucleosomal structures, with enrichment in linker DNA regions. Jagged ends of urinary DNA could potentially serve as a new biomarker for bladder cancer detection. The study was published in the April, 2021 issue of the journal Clinical Chemistry.
Related Links:
The Chinese University of Hong Kong
Promega
Illumina
Latest Molecular Diagnostics News
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more